Euroopa Liit - eesti - EMA (European Medicines Agency)

pfizer europe ma eeig - parekoksiibnaatrium - valu, postoperatiivne - coxibs, antiinflammatory and antirheumatic products - operatsioonijärgse valu lühiajaliseks raviks.

Eesti - eesti - Ravimiamet

krka d.d. novo mesto - tselekoksiib - kõvakapsel - 200mg 10tk; 200mg 90tk; 200mg 30tk; 200mg 20tk; 200mg 50tk; 200mg 60tk; 200mg 40tk; 200mg 100tk

Eesti - eesti - Ravimiamet

krka d.d. novo mesto - tselekoksiib - kõvakapsel - 100mg 30tk; 100mg 50tk; 100mg 100tk; 100mg 60tk; 100mg 40tk; 100mg 20tk

Eesti - eesti - Ravimiamet

first pharma oÜ - tselekoksiib - kõvakapsel - 200mg 30tk; 200mg 10tk; 200mg 90tk; 200mg 50tk; 200mg 40tk; 200mg 20tk; 200mg 100tk

Eesti - eesti - Ravimiamet

accord healthcare b.v. - tselekoksiib - kõvakapsel - 200mg 60tk; 200mg 40tk; 200mg 1tk; 200mg 50tk; 200mg 10tk; 200mg 30tk

Eesti - eesti - Ravimiamet

accord healthcare b.v. - tselekoksiib - kõvakapsel - 100mg 10tk; 100mg 20tk; 100mg 100tk; 100mg 40tk; 100mg 50tk; 100mg 30tk; 100mg 60tk; 100mg 1tk

Eesti - eesti - Ravimiamet

ideal trade links uab - tselekoksiib - kõvakapsel - 200mg 30tk; 200mg 20tk; 200mg 100tk; 200mg 40tk; 200mg 50tk

Eesti - eesti - Ravimiamet

inteli generics nord uab - tselekoksiib - kõvakapsel - 200mg 30tk; 200mg 40tk; 200mg 10tk; 200mg 100tk; 200mg 60tk; 200mg 20tk

Eesti - eesti - Ravimiamet

inteli generics nord uab - tselekoksiib - kõvakapsel - 100mg 100tk; 100mg 40tk; 100mg 20tk; 100mg 10tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - muud antineoplastilised ained - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.